Research ArticleMetabolism, Transport, and Pharmacogenomics
Refining the UGT1A Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens
Éric Lévesque, Anne-Sophie Bélanger, Mario Harvey, Félix Couture, Derek Jonker, Federico Innocenti, Erica Cecchin, Giuseppe Toffoli and Chantal Guillemette
Journal of Pharmacology and Experimental Therapeutics April 2013, 345 (1) 95-101; DOI: https://doi.org/10.1124/jpet.112.202242
Éric Lévesque
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Anne-Sophie Bélanger
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Mario Harvey
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Félix Couture
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Derek Jonker
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Federico Innocenti
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Erica Cecchin
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Giuseppe Toffoli
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
Chantal Guillemette
Pharmacogenomics Laboratory, Centre Hospitalier de l’Université Laval (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada (E.L., A.-S.B., M.H., F.C., C.G.); Hematology-Oncology Department, CHU de Québec Research Center, Hôtel-Dieu de Quebec, Laval University, Quebec, Canada (E.L., F.C.); Hematology-Oncology Department, Ottawa Hospital, Ottawa University, Ontario, Canada (D.J.); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (F.I.); and Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy (E.C., G.T.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleMetabolism, Transport, and Pharmacogenomics
Irinotecan Pharmacogenetics
Éric Lévesque, Anne-Sophie Bélanger, Mario Harvey, Félix Couture, Derek Jonker, Federico Innocenti, Erica Cecchin, Giuseppe Toffoli and Chantal Guillemette
Journal of Pharmacology and Experimental Therapeutics April 1, 2013, 345 (1) 95-101; DOI: https://doi.org/10.1124/jpet.112.202242
Research ArticleMetabolism, Transport, and Pharmacogenomics
Irinotecan Pharmacogenetics
Éric Lévesque, Anne-Sophie Bélanger, Mario Harvey, Félix Couture, Derek Jonker, Federico Innocenti, Erica Cecchin, Giuseppe Toffoli and Chantal Guillemette
Journal of Pharmacology and Experimental Therapeutics April 1, 2013, 345 (1) 95-101; DOI: https://doi.org/10.1124/jpet.112.202242
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement